Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Proliferative Vitreoretinopathy (PVR) Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Proliferative Vitreoretinopathy (PVR) Overview | 7 | 1 |
| Pipeline Products for Proliferative Vitreoretinopathy (PVR) Comparative Analysis | 8 | 1 |
| Proliferative Vitreoretinopathy (PVR) Therapeutics under Development by Companies | 9 | 1 |
| Proliferative Vitreoretinopathy (PVR) Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Proliferative Vitreoretinopathy (PVR) Pipeline Products Glance | 11 | 1 |
| Early Stage Products | 11 | 1 |
| Proliferative Vitreoretinopathy (PVR) Products under Development by Companies | 12 | 1 |
| Proliferative Vitreoretinopathy (PVR) Products under Investigation by Universities/Institutes | 13 | 1 |
| Proliferative Vitreoretinopathy (PVR) Companies Involved in Therapeutics Development | 14 | 3 |
| Novartis AG | 14 | 1 |
| Promedior, Inc. | 15 | 1 |
| RXi Pharmaceuticals Corporation | 16 | 1 |
| Proliferative Vitreoretinopathy (PVR) Therapeutics Assessment | 17 | 8 |
| Assessment by Monotherapy Products | 17 | 1 |
| Assessment by Target | 18 | 2 |
| Assessment by Mechanism of Action | 20 | 2 |
| Assessment by Route of Administration | 22 | 1 |
| Assessment by Molecule Type | 23 | 2 |
| Drug Profiles | 25 | 7 |
| Antisense RNAi Oligonucleotide to Inhibit CTGF for PVR Drug Profile | 25 | 1 |
| Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy Drug Profile | 26 | 1 |
| LD-224 Drug Profile | 27 | 1 |
| PRM-167 Drug Profile | 28 | 2 |
| Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy Drug Profile | 30 | 1 |
| XOMA-089 Drug Profile | 31 | 1 |
| Proliferative Vitreoretinopathy (PVR) Dormant Projects | 32 | 1 |
| Proliferative Vitreoretinopathy (PVR) Product Development Milestones | 33 | 4 |
| Featured News &Press Releases | 33 | 1 |
| Apr 27, 2015: RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences | 33 | 1 |
| May 22, 2014: RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering (sd-rxRNA) Technology Platform | 34 | 1 |
| May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting | 35 | 1 |
| May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting | 36 | 1 |
| Appendix | 37 | 2 |
| Methodology | 37 | 1 |
| Coverage | 37 | 1 |
| Secondary Research | 37 | 1 |
| Primary Research | 37 | 1 |
| Expert Panel Validation | 37 | 1 |
| Contact Us | 37 | 1 |
| Disclaimer | 38 | 1 |